Several PI3K/mTOR/Akt inhibitor candidates, including LY, WM, and rapamycin, which are generally known anti-cancer drugs and immunosuppressors, can prevent GR phosphorylation at Ser211, thereby decreasing GR translocation into nucleus 27. Here, AKT1 is linked to cancer.